Comparative effectiveness and safety of non-Vitamin K antagonist oral anticoagulants and warfarin in patients with Atrial fibrillation: Propensity weighted nationwide cohort study

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Larsen, Torben Bjerregaard ^a,b   Skjøth, Flemming ^a,b   Nielsen, Peter Brønnum ^b   Kjældgaard, Jette Nordstrøm ^b   Lip, Gregory Y H ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DENMARK; DRUG ADMINISTRATION; HEMORRHAGE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROPENSITY SCORE; REGISTER; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; DENMARK; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FEMALE; HEMORRHAGE; HUMANS; MALE; PROPENSITY SCORE; PYRAZOLES; PYRIDONES; REGISTRIES; RIVAROXABAN; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84975519363     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3189     Document Type: Article

References (32)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee, and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51. doi: 10.1056/NEJMoa0905561
2. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91. doi: 10.1056/NEJMoa1009638
3. Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees, and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92. doi: 10.1056/NEJMoa1107039
4. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104. doi: 10.1056/NEJMoa1310907
5. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413. doi: 10.1093/europace/eus305
6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy, and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62. doi: 10.1016/S0140-6736(13)62343-0
7. Olesen JB, Sørensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015; 17: 187-93. doi: 10.1093/europace/euu225
8. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(Suppl): 38-41. doi: 10.1177/1403494810394717
9. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(Suppl): 30-3. doi: 10.1177/1403494811401482
10. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(Suppl): 22-5. doi: 10.1177/1403494810387965
11. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28: 150-4. doi: 10.1159/000102143
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67. doi: 10.7326/0003-4819-146-12-200706190-00007
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. doi: 10.1002/(SICI)1097-0258(19990330)18: 63.0.CO; 2
14. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100. doi: 10.1378/chest.10-0134
15. Robins JM, Hernán MA, Brumback B. Marginal structural models, and causal inference in epidemiology. Epidemiology 2000; 11: 550-60. doi: 10.1097/00001648-200009000-00011
16. Stürmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med 2014; 275: 570-80. doi: 10.1111/joim.12197
17. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013; 32: 3388-414. doi: 10.1002/sim.5753
18. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation, and Monte Carlo simulations. Biom J 2009; 51: 171-84. doi: 10.1002/bimj.200810488
19. Lee SI, Sayers M, Lip GYH, Lane DA. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract 2015; 69: 1341-8. doi: 10.1111/ijcp.12712
20. Shields AM, Lip GYH. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med 2015; 278: 1-18. doi: 10.1111/joim.12360
21. Diener H-C, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant, and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2016; : ehv643; Epub ahead of print. doi: 10.1093/eurheartj/ehw069
22. Diener H-C, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant, and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2016; : ehv643; Epub ahead of print. doi: 10.1093/eurheartj/ehv643
23. Lip GYH, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?Am J Med 2010; 123: 785-9. doi: 10.1016/j.amjmed.2010.01.031
24. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-507. doi: 10.1093/europace/euv309
25. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design, and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635-41. doi: 10.1016/j.ahj.2010.06.042
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee, and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51. doi: 10.1056/NEJMoa0905561
27. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee, and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17. doi: 10.1056/NEJMoa1007432
28. Cohen D. Rivaroxaban: can we trust the evidence?BMJ 2016; 352: i575. doi: 10.1136/bmj.i575
29. Patel MR, Hellkamp AS, Fox KAA. ROCKET AF Executive Committee, and Investigators. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. N Engl J Med 2016; 374: 785-8. doi: 10.1056/NEJMc1515842
30. Wang K-L, Lip GYH, Lin S-J, Chiang C-E. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke 2015; 46: 2555-61. doi: 10.1161/STROKEAHA.115.009947
31. Chiang C-E, Wang K-L, Lip GYH. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-97. doi: 10.1160/TH13-11-0948
32. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges, and implications for drug development. Clin Pharmacol Ther 2011; 90: 777-90. doi: 10.1038/clpt.2011.235